DB15389InvestigationalProtein Based Therapies
Teceleukin is under investigation in clinical trial NCT03610490 (Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Osteosarcoma, or Pancreatic Ductal Adenocarcinoma).
- Code names
- RO-236019
Resolves to
Compound
What you can answer from here — as of April 23, 2025
Which companies are running trials of Teceleukin, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account